Claims

We claim:

1. A compound of formula (I)



wherein

R^1 is the OH or NHOH;

R^2 is H, alkyl, alkenyl, alkynyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl, cycloalkylalkyl, heterocyclo or heterocycloalkyl (any of which may be optionally substituted with one or more substituents selected from R^6, W and WR^6); and

R^3 is H or alkyl;

or R^2, R^3 and the carbon atom to which they are attached together represent a carbocyclic or heterocyclic ring (either of which may be substituted with one or more substituents selected from R^6, W and WR^6);

R^4 is alkyl, cycloalkyl, OR^9, CO_2R^{14}, COR^{10}, $S(O)_qR^{10}$ where q is 0, 1 or 2, $CONR^7R^8$, CN or $S(O)_qNR^7R^8$; two R^4 substituents may be attached to the same carbon atom to form $C(R^4)_2$, where each R^4 is the same or different, or $C(R^4)_2$ may represent C=O;

R^5 is alkyl, cycloalkyl, aryl, heteroaryl, heterocyclo, CF_3, OR^9, COR^{10}, $S(O)_qR^{10}$, CO_2R^{14}, $CONR^7R^8$, $S(O)_qNR^7R^8$, halogen, $NR^{10}R^{11}$ or CN, or two adjacent R^5 substituents may be combined to form a heterocyclic ring;

R^6 is OR^9, COR^{10}, CO_2R^{15}, $CONR^7R^8$, $NR^{10}R^{11}$, $S(O)_qR^{10}$, $S(O)_qNR^7R^8$, =O, =NOR^{10}, succinimido or the group



R^7 and R^8, which may the same or different, are each H, alkyl, cycloalkyl, aryl, heteroaryl, heterocyclo, arylalkyl, heteroarylalkyl, heterocycloalkyl or cycloalkylalkyl, or R^7 and R^8 and the nitrogen to which they are attached together represent a heterocyclic ring;

R^9 is H, alkyl, CF_3, CHF_2, CH_2F, cycloalkyl, aryl, heteroaryl, heterocyclo, arylalkyl, heteroarylalkyl, heterocycloalkyl or cycloalkylalkyl;

R^{10} is H, alkyl, cycloalkyl, aryl, heteroaryl, heterocyclo, arylalkyl, heteroarylalkyl, heterocycloalkyl or cycloalkylalkyl; and

R^{11} is H, alkyl, cycloalkyl, aryl, heteroaryl, heterocyclo, arylalkyl, heteroarylalkyl, heterocycloalkyl, cycloalkylalkyl, COR^{12}, $CONR^7R^8$, $S(O)_qR^{12}$ or $S(O)_qNR^7R^8$;

or R^{10} and R^{11} and the nitrogen to which they are attached together represent a heterocyclic ring;

R^{12} is OR^9 or R^{13};

R^{13} is alkyl, cycloalkyl, aryl, heteroaryl, heterocyclo, arylalkyl, heteroarylalkyl, heterocycloalkyl or cycloalkylalkyl;

R^{14} is H, alkyl or cycloalkyl;

R^{15} is H, alkyl, cycloalkyl, arylalkyl or heteroarylalkyl;

X is a bond (i.e. is absent), -O-, -C(O)-, $-S(O)_q$-, $-N(R^{11})$-, $-N(R^{11})C(R^{16})_2$-, $-S(O)_qC(R^{16})_2$-, $-C(R^{16})_2N(R^{11})$-, $C(R^{16})_2S(O)_q$-, $-C(R^{16})$=N-, $-N=C(R^{16})$-, $-N(R^{11})SO_2$-, $-SO_2N(R^{11})$-, $-N(R^{11})$CO- or $-CON(R^{11})$-; and the R^{16} groups in $C(R^{16})_2$ may be the same or different;

Y is a bond (i.e. is absent), -O-, -C(O)-, $-S(O)_q$-, $-N(R^{11})$-, $-N(R^{11})C(R^{16})_2$-, $-S(O)_qC(R^{16})_2$-, $-C(R^{16})_2N(R^{11})$-, $-C(R^{16})_2S(O)_q$-, $-C(R^{16})$=N-, $-N=C(R^{16})$-, $N(R^{11})SO_2$-,

$-SO_2N(R^{11})-$, $-N(R^{11})CO-$ or $-CON(R^{11})-$; and the R^{16} groups in $C(R^{16})_2$ may be the same or different;

R^{16} is H, alkyl, cycloalkyl, OR^9, CO_2R^{14}, COR^{10}, $S(O)_qR^{10}$, $CONR^7R^8$, CN or $S(O)_qNR^7R^8$;

R^{17} is H or alkyl;

W is alkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclo or heterocycloalkyl;

---- represents a single or double bond;

each k and m is independently 0, 1, 2 or 3;

n is 0, 1 or 2; and

p is 0, 1 or 2, provided that n+p does not exceed 3;

or a salt, solvate, hydrate, N-oxide, protected amino, protected carboxy or protected hydroxamic acid thereof.

2. The compound of claim 1, wherein R^1 is NHOH.

3. The compound of claim 1, wherein p is 1; R^4 is alkyl, cycloalkyl, OR^9, CO_2R^{14}, COR^{10}, $S(O)_qR^{10}$, $CONR^7R^8$, CN or, $S(O)_qNR^7R^8$, or $C(R^4)_2$ may represent C=O; R^6 is not succinimido or the said group; when R^6 is CO_2R^{15}, R^{15} is H, alkyl or cycloalkyl; and n is 1 or 2.

4. The compound of claim 1, which is selected from

3-methyl-2-(1,3,4,9-tetrahydro-β-carboline-2-sulfonylmethyl)butyric acid,

2-(6-methoxy-1,3,4,9-tetrahydro-β-carboline-2sulfonylmethyl)-3-methylbutyric acid,

2-(3,4-dihydro-1H-benzo[4,5]furo[2,3-c]pyridine-2-sulfonylmethyl)-3-methylbutyric acid,

N-hydroxy-3-methyl-2-(1,3,4,9-tetrahydro-β-carboline-2-sulfonylmethyl)-butyramide,

2-(3,4-dihydro-1H-benzo[4,5]furo[2,3-c]pyridine-2-sulfonylmethyl-N-hydroxy-3-

methylbutyramide, and

N-hydroxy-2-(6-methoxy-1,3,4,9-tetrahydro-β-carboline-2-sulfonylmethyl)-3-methylbutyramide.

5. The compound of claim 1, which is selected from

2-[2-(1-benzyloxycarbonylpiperidin-4-yl)-2-carboxyethanesulfonyl]-1,2,3,4-tetrahydro-β-carboline-9-carboxylic acid 2,2,2-trichloroethyl ester,

4-(1,3,4,9-tetrahydro-β-carboline-2-sulfonylmethyl)-tetrahydropyran-4-carboxylic acid,

2-(R)-(3,4-dihydro-1H-benzo[4,5]thieno[2,3-c]pyridine-2-sulfonylmethyl-3-methylbutyric acid,

4-(3,4-dihydro-1H-benzo[4,5]thieno[2,3-c]pyridine-2-sulfonylmethyl)-tetrahydropyran-4-carboxylic acid,

2-[2-(1-benzyloxycarbonyl-piperidin-4-yl)-2-hydroxy carbamoylethanesulfonyl]-1,2,3,4-tetrahydro-β-carboline-9-carboxylic acid 2,2,2-trichloroethyl ester,

(1,3,4,9-tetrahydro-β-carboline-2-sulfonylmethyl)tetrahydropyran-4-carboxylic acid hydroxamide,

2-(R)-(3,4-dihydro-1H-benzo[4,5]thieno[2,3-c]pyridine-2-sulfonylmethyl-N-hydroxy-3-methylbutyramide,

4-(3,4-dihydro-1H-benzo[4,5]thieno[2,3-c]pyridine-2-sulfonylmethyl)-tetrahydropyran-4-carboxylic acid hydroxamide, and

4-[1-hydroxycarbamoyl-2-(1,3,4,9-tetrahydro-β-carboline-2-sulfonyl)ethyl]-piperidine-1-carboxylic acid benzyl ester.

6. A pharmaceutical composition for use in therapy, comprising a compound of formula (I)



wherein

R^1 is the OH or NHOH;

R^2 is H, alkyl, alkenyl, alkynyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl, cycloalkylalkyl, heterocyclo or heterocycloalkyl (any of which may be optionally substituted with one or more substituents selected from R^6, W and WR^6); and

R^3 is H or alkyl;

or R^2, R^3 and the carbon atom to which they are attached together represent a carbocyclic or heterocyclic ring (either of which may be substituted with one or more substituents selected from R^6, W and WR^6);

R^4 is alkyl, cycloalkyl, OR^9, CO_2R^{14}, COR^{10}, $S(O)_qR^{10}$ where q is 0, 1 or 2, $CONR^7R^8$, CN or $S(O)_qNR^7R^8$; two R^4 substituents may be attached to the same carbon atom to form $C(R^4)_2$, where each R^4 is the same or different, or $C(R^4)_2$ may represent C=O;

R^5 is alkyl, cycloalkyl, aryl, heteroaryl, heterocyclo, CF_3, OR^9, COR^{10}, $S(O)_qR^{10}$, CO_2R^{14}, $CONR^7R^8$, $S(O)_qNR^7R^8$, halogen, $NR^{10}R^{11}$ or CN, or two adjacent R^5 substituents may be combined to form a heterocyclic ring;

R^6 is OR^9, COR^{10}, CO_2R^{15}, $CONR^7R^8$, $NR^{10}R^{11}$, $S(O)_qR^{10}$, $S(O)_qNR^7R^8$, =O, =NOR^{10}, succinimido or the group



R^7 and R^8, which may the same or different, are each H, alkyl, cycloalkyl, aryl, heteroaryl, heterocyclo, arylalkyl, heteroarylalkyl, heterocycloalkyl or cycloalkylalkyl, or R^7 and R^8 and the nitrogen to which they are attached together represent a heterocyclic ring;

R^9 is H, alkyl, CF_3, CHF_2, CH_2F, cycloalkyl, aryl, heteroaryl, heterocyclo, arylalkyl, heteroarylalkyl, heterocycloalkyl or cycloalkylalkyl;

R^{10} is H, alkyl, cycloalkyl, aryl, heteroaryl, heterocyclo, arylalkyl, heteroarylalkyl,

heterocycloalkyl or cycloalkylalkyl; and

R^{11} is H, alkyl, cycloalkyl, aryl, heteroaryl, heterocyclo, arylalkyl, heteroarylalkyl, heterocycloalkyl, cycloalkylalkyl, COR^{12}, $CONR^7R^8$, $S(O)_qR^{12}$ or $S(O)_qNR^7R^8$;

or R^{10} and R^{11} and the nitrogen to which they are attached together represent a heterocyclic ring;

R^{12} is OR^9 or R^{13};

R^{13} is alkyl, cycloalkyl, aryl, heteroaryl, heterocyclo, arylalkyl, heteroarylalkyl, heterocycloalkyl or cycloalkylalkyl;

R^{14} is H, alkyl or cycloalkyl;

R^{15} is H, alkyl, cycloalkyl, arylalkyl or heteroarylalkyl;

X is a bond (i.e. is absent), -O-, -C(O)-, $-S(O)_q-$, $-N(R^{11})-$, $-N(R^{11})C(R^{16})_2-$, $-S(O)_qC(R^{16})_2-$, $-C(R^{16})_2N(R^{11})-$, $C(R^{16})_2S(O)_q-$, $-C(R^{16})=N-$, $-N=C(R^{16})-$, $-N(R^{11})SO_2-$, $-SO_2N(R^{11})-$, $-N(R^{11})CO-$ or $-CON(R^{11})-$; and the R^{16} groups in $C(R^{16})_2$ may be the same or different;

Y is a bond (i.e. is absent), -O-, -C(O)-, $-S(O)_q-$, $-N(R^{11})-$, $-N(R^{11})C(R^{16})_2-$, $-S(O)_qC(R^{16})_2-$, $-C(R^{16})_2N(R^{11})-$, $-C(R^{16})_2S(O)_q-$, $-C(R^{16})=N-$, $-N=C(R^{16})-$, $N(R^{11})SO_2-$, $-SO_2N(R^{11})-$, $-N(R^{11})CO-$ or $-CON(R^{11})-$; and the R^{16} groups in $C(R^{16})_2$ may be the same or different;

R^{16} is H, alkyl, cycloalkyl, OR^9, CO_2R^{14}, COR^{10}, $S(O)_qR^{10}$, $CONR^7R^8$, CN or $S(O)_qNR^7R^8$;

R^{17} is H or alkyl;

W is alkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclo or heterocycloalkyl;

---- represents a single or double bond;

each k and m is independently 0, 1, 2 or 3;

n is 0, 1 or 2; and

p is 0, 1 or 2, provided that n+p does not exceed 3;

or a salt, solvate, hydrate, N-oxide, protected amino, protected carboxy or protected hydroxamic acid thereof;

and a pharmaceutically-acceptable diluent or carrier.

7. The composition of claim 6, wherein wherein R^1 is NHOH.

8. The composition of claim 6, wherein p is 1; R^4 is alkyl, cycloalkyl, OR^9, CO_2R^{14}, COR^{10}, $S(O)_qR^{10}$, $CONR^7R^8$, CN or, $S(O)_qNR^7R^8$, or $C(R^4)_2$ may represent C=O; R^6 is not succinimido or the said group; when R^6 is CO_2R^{15}, R^{15} is H, alkyl or cycloalkyl; and n is 1 or 2.

9. The composition of claim 6, wherein said compound is selected from

3-methyl-2-(1,3,4,9-tetrahydro-β-carboline-2-sulfonylmethyl)butyric acid,

2-(6-methoxy-1,3,4,9-tetrahydro-β-carboline-2sulfonylmethyl)-3-methylbutyric acid,

2-(3,4-dihydro-1H-benzo[4,5]furo[2,3-c]pyridine-2-sulfonylmethyl)-3-methylbutyric acid,

N-hydroxy-3-methyl-2-(1,3,4,9-tetrahydro-β-carboline-2-sulfonylmethyl)-butyramide,

2-(3,4-dihydro-1H-benzo[4,5]furo[2,3-c]pyridine-2-sulfonylmethyl-N-hydroxy-3-methylbutyramide, and

N-hydroxy-2-(6-methoxy-1,3,4,9-tetrahydro-β-carboline-2-sulfonylmethyl)-3-methylbutyramide.

10. The composition of claim 6, wherein said compound is selected from

2-[2-(1-benzyloxycarbonylpiperidin-4-yl)-2-carboxyethanesulfonyl]-1,2,3,4-tetrahydro-β-carboline-9-carboxylic acid 2,2,2-trichloroethyl ester,

4-(1,3,4,9-tetrahydro-β-carboline-2-sulfonylmethyl)-tetrahydropyran-4-carboxylic acid,

2-(R)-(3,4-dihydro-1H-benzo[4,5]thieno[2,3-c]pyridine-2-sulfonylmethyl-3-methylbutyric acid,

4-(3,4-dihydro-1H-benzo[4,5]thieno[2,3-c]pyridine-2-sulfonylmethyl)-

tetrahydropyran-4-carboxylic acid,

2-[2-(1-benzyloxycarbonyl-piperidin-4-yl)-2-hydroxy carbamoylethanesulfonyl]-1,2,3,4-tetrahydro-β-carboline-9-carboxylic acid 2,2,2-trichloroethyl ester,

(1,3,4,9-tetrahydro-β-carboline-2-sulfonylmethyl)tetrahydropyran-4-carboxylic acid hydroxamide,

2-(R)-(3,4-dihydro-1H-benzo[4,5]thieno[2,3-c]pyridine-2-sulfonylmethyl-N-hydroxy-3-methylbutyramide,

4-(3,4-dihydro-1H-benzo[4,5]thieno[2,3-c]pyridine-2-sulfonylmethyl)-tetrahydropyran-4-carboxylic acid hydroxamide, and

4-[1-hydroxycarbamoyl-2-(1,3,4,9-tetrahydro-β-carboline-2-sulfonyl)ethyl]-piperidine-1-carboxylic acid benzyl ester.

11. A method for the treatment of cancer; inflamation; or an autoimmune, infectious or ocular disease; wherein said method comprises administering to a patient in need of such treatment an effective amount of a compound of formula (I)



wherein

R^1 is the OH or NHOH;

R^2 is H, alkyl, alkenyl, alkynyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl, cycloalkylalkyl, heterocyclo or heterocycloalkyl (any of which may be optionally substituted with one or more substituents selected from R^6, W and WR^6); and

R^3 is H or alkyl;

or R^2, R^3 and the carbon atom to which they are attached together represent a

carbocyclic or heterocyclic ring (either of which may be substituted with one or more substituents selected from R^6, W and WR^6);

R^4 is alkyl, cycloalkyl, OR^9, CO_2R^{14}, COR^{10}, $S(O)_qR^{10}$ where q is 0, 1 or 2, $CONR^7R^8$, CN or $S(O)_qNR^7R^8$; two R^4 substituents may be attached to the same carbon atom to form $C(R^4)_2$, where each R^4 is the same or different, or $C(R^4)_2$ may represent C=O;

R^5 is alkyl, cycloalkyl, aryl, heteroaryl, heterocyclo, CF_3, OR^9, COR^{10}, $S(O)_qR^{10}$, CO_2R^{14}, $CONR^7R^8$, $S(O)_qNR^7R^8$, halogen, $NR^{10}R^{11}$ or CN, or two adjacent R^5 substituents may be combined to form a heterocyclic ring;

R^6 is OR^9, COR^{10}, CO_2R^{15}, $CONR^7R^8$, $NR^{10}R^{11}$, $S(O)_qR^{10}$, $S(O)_qNR^7R^8$, =O, =NOR^{10}, succinimido or the group



R^7 and R^8, which may the same or different, are each H, alkyl, cycloalkyl, aryl, heteroaryl, heterocyclo, arylalkyl, heteroarylalkyl, heterocycloalkyl or cycloalkylalkyl, or R^7 and R^8 and the nitrogen to which they are attached together represent a heterocyclic ring;

R^9 is H, alkyl, CF_3, CHF_2, CH_2F, cycloalkyl, aryl, heteroaryl, heterocyclo, arylalkyl, heteroarylalkyl, heterocycloalkyl or cycloalkylalkyl;

R^{10} is H, alkyl, cycloalkyl, aryl, heteroaryl, heterocyclo, arylalkyl, heteroarylalkyl, heterocycloalkyl or cycloalkylalkyl; and

R^{11} is H, alkyl, cycloalkyl, aryl, heteroaryl, heterocyclo, arylalkyl, heteroarylalkyl, heterocycloalkyl, cycloalkylalkyl, COR^{12}, $CONR^7R^8$, $S(O)_qR^{12}$ or $S(O)_qNR^7R^8$;

or R^{10} and R^{11} and the nitrogen to which they are attached together represent a heterocyclic ring;

R^{12} is OR^9 or R^{13};

R^{13} is alkyl, cycloalkyl, aryl, heteroaryl, heterocyclo, arylalkyl, heteroarylalkyl,

heterocycloalkyl or cycloalkylalkyl;

R^{14} is H, alkyl or cycloalkyl;

R^{15} is H, alkyl, cycloalkyl, arylalkyl or heteroarylalkyl;

X is a bond (i.e. is absent), -O-, -C(O)-, $-S(O)_q-$, $-N(R^{11})-$, $-N(R^{11})C(R^{16})_2-$, $-S(O)_qC(R^{16})_2-$, $-C(R^{16})_2N(R^{11})-$, $C(R^{16})_2S(O)_q-$, $-C(R^{16})=N-$, $-N=C(R^{16})-$, $-N(R^{11})SO_2-$, $-SO_2N(R^{11})-$, $-N(R^{11})CO-$ or $-CON(R^{11})-$; and the R^{16} groups in $C(R^{16})_2$ may be the same or different;

Y is a bond (i.e. is absent), -O-, -C(O)-, $-S(O)_q-$, $-N(R^{11})-$, $-N(R^{11})C(R^{16})_2-$, $-S(O)_qC(R^{16})_2-$, $-C(R^{16})_2N(R^{11})-$, $-C(R^{16})_2S(O)_q-$, $-C(R^{16})=N-$, $-N=C(R^{16})-$, $N(R^{11})SO_2-$, $-SO_2N(R^{11})-$, $-N(R^{11})CO-$ or $-CON(R^{11})-$; and the R^{16} groups in $C(R^{16})_2$ may be the same or different;

R^{16} is H, alkyl, cycloalkyl, OR^9, CO_2R^{14}, COR^{10}, $S(O)_qR^{10}$, $CONR^7R^8$, CN or $S(O)_qNR^7R^8$;

R^{17} is H or alkyl;

W is alkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclo or heterocycloalkyl;

---- represents a single or double bond;

each k and m is independently 0, 1, 2 or 3;

n is 0, 1 or 2; and

p is 0, 1 or 2, provided that n+p does not exceed 3;

or a salt, solvate, hydrate, N-oxide, protected amino, protected carboxy or protected hydroxamic acid thereof.

12. The method of claim 11, wherein wherein R^1 is NHOH.

13. The method of claim 11, wherein p is 1; R^4 is alkyl, cycloalkyl, OR^9, CO_2R^{14}, COR^{10}, $S(O)_qR^{10}$, $CONR^7R^8$, CN or, $S(O)_qNR^7R^8$, or $C(R^4)_2$ may represent C=O; R^6 is not succinimido or the said group; when R^6 is CO_2R^{15}, R^{15} is H, alkyl or cycloalkyl; and n is 1 or 2.

14. The method of claim 11, wherein said compound is selected from

3-methyl-2-(1,3,4,9-tetrahydro-β-carboline-2-sulfonylmethyl)butyric acid,

2-(6-methoxy-1,3,4,9-tetrahydro-β-carboline-2sulfonylmethyl)-3-methylbutyric acid,

2-(3,4-dihydro-1H-benzo[4,5]furo[2,3-c]pyridine-2-sulfonylmethyl)-3-methylbutyric acid,

N-hydroxy-3-methyl-2-(1,3,4,9-tetrahydro-β-carboline-2-sulfonylmethyl)-butyramide,

2-(3,4-dihydro-1H-benzo[4,5]furo[2,3-c]pyridine-2-sulfonylmethyl-N-hydroxy-3-methylbutyramide, and

N-hydroxy-2-(6-methoxy-1,3,4,9-tetrahydro-β-carboline-2-sulfonylmethyl)-3-methylbutyramide.

15. The method of claim 11, wherein said compound is selected from

2-[2-(1-benzyloxycarbonylpiperidin-4-yl)-2-carboxyethanesulfonyl]-1,2,3,4-tetrahydro-β-carboline-9-carboxylic acid 2,2,2-trichloroethyl ester,

4-(1,3,4,9-tetrahydro-β-carboline-2-sulfonylmethyl)-tetrahydropyran-4-carboxylic acid,

2-(R)-(3,4-dihydro-1H-benzo[4,5]thieno[2,3-c]pyridine-2-sulfonylmethyl-3-methylbutyric acid,

4-(3,4-dihydro-1H-benzo[4,5]thieno[2,3-c]pyridine-2-sulfonylmethyl)-tetrahydropyran-4-carboxylic acid,

2-[2-(1-benzyloxycarbonyl-piperidin-4-yl)-2-hydroxy carbamoylethanesulfonyl]-1,2,3,4-tetrahydro-β-carboline-9-carboxylic acid 2,2,2-trichloroethyl ester,

(1,3,4,9-tetrahydro-β-carboline-2-sulfonylmethyl)tetrahydropyran-4-carboxylic acid hydroxamide,

2-(R)-(3,4-dihydro-1H-benzo[4,5]thieno[2,3-c]pyridine-2-sulfonylmethyl-N-hydroxy-3-methylbutyramide,

4-(3,4-dihydro-1H-benzo[4,5]thieno[2,3-c]pyridine-2-sulfonylmethyl)-tetrahydropyran-4-carboxylic acid hydroxamide, and

4-[1-hydroxycarbamoyl-2-(1,3,4,9-tetrahydro-β-carboline-2-sulfonyl)ethyl]-piperidine-1-carboxylic acid benzyl ester.